Published on : Aug 04, 2017
Albany, New York, August 4, 2017: Market Research Hub (MRH) has recently highlighted the pipeline landscape of Intercellular Adhesion Molecule 1 in a new report added to its repository, with a title of “Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Pipeline Review, H2 2017”. The main purpose of this study is to provide an assessment of the various pipeline targeted therapeutics, together with analysis by indications, stage of development, route of administration (RoA), mechanism of action (MoA) and molecule type. Through this analysis, the readers will gain strategically significant competitor information, analysis and key insights to frame effective R&D strategies.
Initially, this pipeline guide covers intercellular Adhesion Molecule 1 (ICAM-1) overview along with precise information on its therapeutic development. This section provides data on targeted therapeutics which are under development by companies and research institutes based on information resulting from company and industry-specific sources. Latest news and deals related to Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics are also mentioned. One of the latest news of related to the targeted therapeutics includes that Atlantic Healthcare, an emerging trans-Atlantic pharmaceutical company has developed tablet formulations of alicaforsen to treat Crohn's disease and Ulcerative Colitis. In addition to targeting ICAM-1, alicaforsen has been shown to target Toll-like receptor 9 (TLR-9).
Intercellular Adhesion Molecule 1 (ICAM-1) is a protein encoded by the ICAM1 gene, which acts as a receptor for major receptor group rhinovirus A-B capsid proteins and Coxsackievirus A21 capsid proteins. The protein is a ligand for lymphocyte-function associated (LFA) antigens and also a receptor for CD11a, b/CD18, fibrinogen, human rhinovirus and Plasmodium falciparum-infected erythrocytes. The ICAM family consists of five members, designated ICAM-1 to ICAM-5. ICAM1 promotes the assembly of endothelial apical cups through ARHGEF26/SGEF and RHOG activation. The report also examines that they are important in inflammation, immune responses and in intracellular signaling events.
Further, the study encapsulates pipeline products which are based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The report covers products from therapy areas Immunology, Oncology, Cardiovascular, Gastrointestinal, Dermatology, Genito Urinary System and Sex Hormones, Hematological Disorders, Metabolic Disorders, Musculoskeletal Disorders and Ophthalmology. Also, a section covering drug profiles for the pipeline products which covers, product descriptive licensing and alliance details, R&D brief and other developmental activities.
Moreover, the report reviews key players involved in Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics and enlists all their major and minor project. Leading companies are Atlantic Healthcare Plc, China Medical System Holdings Ltd., and RXi Pharmaceuticals Corp.
Request a Sample with TOC in a PDF format : http://www.marketresearchhub.com/enquiry.php?type=S&repid=1256874
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : email@example.com